Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction

Abdominal aortic aneurysm (AAA) is a common disease with as yet unclear cause. Increased matrix metalloproteinase (MMP) levels in the plasma and aorta are a consistent finding in AAA. Although the role of MMPs in AAA has largely been attributed to degradation of the extracellular matrix proteins, th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of vascular surgery 2004-11, Vol.40 (5), p.1001-1010
Hauptverfasser: CHEW, David K. W, CONTE, Michael S, KHALIL, Raouf A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1010
container_issue 5
container_start_page 1001
container_title Journal of vascular surgery
container_volume 40
creator CHEW, David K. W
CONTE, Michael S
KHALIL, Raouf A
description Abdominal aortic aneurysm (AAA) is a common disease with as yet unclear cause. Increased matrix metalloproteinase (MMP) levels in the plasma and aorta are a consistent finding in AAA. Although the role of MMPs in AAA has largely been attributed to degradation of the extracellular matrix proteins, the effects of MMPs on the mechanisms of aortic contraction are unclear. The purpose of this study was to test the hypothesis that MMPs promote aortic dilation by inhibiting the Ca2+ mobilization mechanisms of smooth muscle contraction. Isometric contraction and 45Ca2+ influx were measured in aortic strips isolated from male Sprague-Dawley rats treated or not treated with MMP-2 and MMP-9. In normal Krebs solution (2.5 mmol/L Ca2+ ) phenylephrine (10-5 mol/L) caused contraction of the aortic strips, which was significantly inhibited (P < .05) by MMP-2 (maximum, 48.9% +/- 5.0%) and to a greater extent by MMP-9 (maximum, 69.8% +/- 6.2%). The MMP-induced inhibition of phenylephrine contraction depended on concentration and time. The inhibitory effects of MMPs on phenylephrine contraction were reversible. In Ca2+ -free (2 mmol/L ethylene glycol bis[beta-aminoethyl ether]-N,N,N',N'-tetraacetic acid) Krebs solution phenylephrine caused a small contraction that was not inhibited by MMP-2 or MMP-9, which suggests that MMPs do not inhibit Ca2+ release from the intracellular stores. Membrane depolarization with 96 mmol/L of potassium chloride, which stimulates Ca2+ entry from the extracellular space, caused a time-dependent and reversible contraction, which was inhibited by MMP-2 and MMP-9. Histologic studies of MMP-treated tissues stained with hematoxylin-eosin or Verhoeff stain for elastin confirmed the absence of degradation of the extracellular matrix. MMP-2 and MMP-9 also caused significant inhibition of 45Ca2+ influx induced by phenylephrine and potassium chloride. These data suggest that MMP-2 and MMP-9 promote aortic dilation by inhibiting the Ca2+ entry mechanism of vascular smooth muscle contraction. Abdominal aortic aneurysm (AAA) is a slow and progressive disease. The late stages of AAA are characterized by degenerative changes in the extracellular matrix and smooth muscle components of the aortic wall. The present study describes novel inhibitory effects of matrix metalloproteinase (MMP) on the Ca2+ entry mechanisms of aortic smooth muscle contraction, even in the absence of extracellular matrix degradation. The MMP-induced inhibition of aortic contraction may f
doi_str_mv 10.1016/j.jvs.2004.08.035
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67097114</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67097114</sourcerecordid><originalsourceid>FETCH-LOGICAL-c368t-3d1181c3cc4207fbb4aa6eec99ae3604a40363de5e3427d694ea4a4b8dac1aaa3</originalsourceid><addsrcrecordid>eNpFkE1Lw0AQhveg2Fr9AV4kF71I4k52k02OUvyCihc9yjLZTOiWfNTdtNh_75YWehqYed6X4WHsBngCHPLHVbLa-iTlXCa8SLjIztiUKwlxloKcsEvvV5wDZIW6YBPIskyVoKbs5wNHZ_-ijkZs22HthpFsj55ivyZjG2si2y9tZUc79NHQRHNMHyLqR7cLGbPE3vrO7w9b9GbToovMEK5o9oErdt5g6-n6OGfs--X5a_4WLz5f3-dPi9iIvBhjUQMUYIQxMuWqqSqJmBOZskQSOZcouchFTRkJmao6LyVhWFZFjQYQUczY_aE3_P-7IT_qznpDbYs9DRuvc8VLBSADCAfQuMF7R41eO9uh22ngeu9Rr3TwqPceNS908Bgyt8fyTdVRfUocJQbg7ggEBdg2Dntj_YnL07IUSol_mQ2AgA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67097114</pqid></control><display><type>article</type><title>Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>CHEW, David K. W ; CONTE, Michael S ; KHALIL, Raouf A</creator><creatorcontrib>CHEW, David K. W ; CONTE, Michael S ; KHALIL, Raouf A</creatorcontrib><description>Abdominal aortic aneurysm (AAA) is a common disease with as yet unclear cause. Increased matrix metalloproteinase (MMP) levels in the plasma and aorta are a consistent finding in AAA. Although the role of MMPs in AAA has largely been attributed to degradation of the extracellular matrix proteins, the effects of MMPs on the mechanisms of aortic contraction are unclear. The purpose of this study was to test the hypothesis that MMPs promote aortic dilation by inhibiting the Ca2+ mobilization mechanisms of smooth muscle contraction. Isometric contraction and 45Ca2+ influx were measured in aortic strips isolated from male Sprague-Dawley rats treated or not treated with MMP-2 and MMP-9. In normal Krebs solution (2.5 mmol/L Ca2+ ) phenylephrine (10-5 mol/L) caused contraction of the aortic strips, which was significantly inhibited (P &lt; .05) by MMP-2 (maximum, 48.9% +/- 5.0%) and to a greater extent by MMP-9 (maximum, 69.8% +/- 6.2%). The MMP-induced inhibition of phenylephrine contraction depended on concentration and time. The inhibitory effects of MMPs on phenylephrine contraction were reversible. In Ca2+ -free (2 mmol/L ethylene glycol bis[beta-aminoethyl ether]-N,N,N',N'-tetraacetic acid) Krebs solution phenylephrine caused a small contraction that was not inhibited by MMP-2 or MMP-9, which suggests that MMPs do not inhibit Ca2+ release from the intracellular stores. Membrane depolarization with 96 mmol/L of potassium chloride, which stimulates Ca2+ entry from the extracellular space, caused a time-dependent and reversible contraction, which was inhibited by MMP-2 and MMP-9. Histologic studies of MMP-treated tissues stained with hematoxylin-eosin or Verhoeff stain for elastin confirmed the absence of degradation of the extracellular matrix. MMP-2 and MMP-9 also caused significant inhibition of 45Ca2+ influx induced by phenylephrine and potassium chloride. These data suggest that MMP-2 and MMP-9 promote aortic dilation by inhibiting the Ca2+ entry mechanism of vascular smooth muscle contraction. Abdominal aortic aneurysm (AAA) is a slow and progressive disease. The late stages of AAA are characterized by degenerative changes in the extracellular matrix and smooth muscle components of the aortic wall. The present study describes novel inhibitory effects of matrix metalloproteinase (MMP) on the Ca2+ entry mechanisms of aortic smooth muscle contraction, even in the absence of extracellular matrix degradation. The MMP-induced inhibition of aortic contraction may further explain the role of increased MMP activity particularly during the early development of AAA. Chronic exposure to MMPs may lead to protracted inhibition of aortic contraction, progressive aortic dilation, and aneurysm formation. MMP-9 is a more potent inhibitor of aortic contraction than MMP-2, consistent with a more dominant role in AAA. Restoration and preservation of smooth muscle contractile function by specific inhibitors of MMPs may represent a new strategy in preventing the progression of small AAA.</description><identifier>ISSN: 0741-5214</identifier><identifier>DOI: 10.1016/j.jvs.2004.08.035</identifier><identifier>PMID: 15557917</identifier><identifier>CODEN: JVSUES</identifier><language>eng</language><publisher>New York, NY: Elsevier</publisher><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Animals ; Aorta, Thoracic - drug effects ; Aorta, Thoracic - pathology ; Biological and medical sciences ; Biopsy, Needle ; Blood and lymphatic vessels ; Calcium - metabolism ; Cardiology. Vascular system ; Disease Models, Animal ; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous ; Emergency and intensive care: renal failure. Dialysis management ; Immunohistochemistry ; Intensive care medicine ; Male ; Matrix Metalloproteinase 2 - pharmacology ; Matrix Metalloproteinase 9 - pharmacology ; Medical sciences ; Muscle, Smooth, Vascular - drug effects ; Muscle, Smooth, Vascular - physiology ; Probability ; Rats ; Rats, Sprague-Dawley ; Sensitivity and Specificity ; Statistics, Nonparametric ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Vascular surgery: aorta, extremities, vena cava. Surgery of the lymphatic vessels ; Vasoconstriction - drug effects ; Vasoconstriction - physiology ; Vasodilation - drug effects ; Vasodilation - physiology</subject><ispartof>Journal of vascular surgery, 2004-11, Vol.40 (5), p.1001-1010</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c368t-3d1181c3cc4207fbb4aa6eec99ae3604a40363de5e3427d694ea4a4b8dac1aaa3</citedby><cites>FETCH-LOGICAL-c368t-3d1181c3cc4207fbb4aa6eec99ae3604a40363de5e3427d694ea4a4b8dac1aaa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=16299377$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15557917$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CHEW, David K. W</creatorcontrib><creatorcontrib>CONTE, Michael S</creatorcontrib><creatorcontrib>KHALIL, Raouf A</creatorcontrib><title>Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction</title><title>Journal of vascular surgery</title><addtitle>J Vasc Surg</addtitle><description>Abdominal aortic aneurysm (AAA) is a common disease with as yet unclear cause. Increased matrix metalloproteinase (MMP) levels in the plasma and aorta are a consistent finding in AAA. Although the role of MMPs in AAA has largely been attributed to degradation of the extracellular matrix proteins, the effects of MMPs on the mechanisms of aortic contraction are unclear. The purpose of this study was to test the hypothesis that MMPs promote aortic dilation by inhibiting the Ca2+ mobilization mechanisms of smooth muscle contraction. Isometric contraction and 45Ca2+ influx were measured in aortic strips isolated from male Sprague-Dawley rats treated or not treated with MMP-2 and MMP-9. In normal Krebs solution (2.5 mmol/L Ca2+ ) phenylephrine (10-5 mol/L) caused contraction of the aortic strips, which was significantly inhibited (P &lt; .05) by MMP-2 (maximum, 48.9% +/- 5.0%) and to a greater extent by MMP-9 (maximum, 69.8% +/- 6.2%). The MMP-induced inhibition of phenylephrine contraction depended on concentration and time. The inhibitory effects of MMPs on phenylephrine contraction were reversible. In Ca2+ -free (2 mmol/L ethylene glycol bis[beta-aminoethyl ether]-N,N,N',N'-tetraacetic acid) Krebs solution phenylephrine caused a small contraction that was not inhibited by MMP-2 or MMP-9, which suggests that MMPs do not inhibit Ca2+ release from the intracellular stores. Membrane depolarization with 96 mmol/L of potassium chloride, which stimulates Ca2+ entry from the extracellular space, caused a time-dependent and reversible contraction, which was inhibited by MMP-2 and MMP-9. Histologic studies of MMP-treated tissues stained with hematoxylin-eosin or Verhoeff stain for elastin confirmed the absence of degradation of the extracellular matrix. MMP-2 and MMP-9 also caused significant inhibition of 45Ca2+ influx induced by phenylephrine and potassium chloride. These data suggest that MMP-2 and MMP-9 promote aortic dilation by inhibiting the Ca2+ entry mechanism of vascular smooth muscle contraction. Abdominal aortic aneurysm (AAA) is a slow and progressive disease. The late stages of AAA are characterized by degenerative changes in the extracellular matrix and smooth muscle components of the aortic wall. The present study describes novel inhibitory effects of matrix metalloproteinase (MMP) on the Ca2+ entry mechanisms of aortic smooth muscle contraction, even in the absence of extracellular matrix degradation. The MMP-induced inhibition of aortic contraction may further explain the role of increased MMP activity particularly during the early development of AAA. Chronic exposure to MMPs may lead to protracted inhibition of aortic contraction, progressive aortic dilation, and aneurysm formation. MMP-9 is a more potent inhibitor of aortic contraction than MMP-2, consistent with a more dominant role in AAA. Restoration and preservation of smooth muscle contractile function by specific inhibitors of MMPs may represent a new strategy in preventing the progression of small AAA.</description><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Animals</subject><subject>Aorta, Thoracic - drug effects</subject><subject>Aorta, Thoracic - pathology</subject><subject>Biological and medical sciences</subject><subject>Biopsy, Needle</subject><subject>Blood and lymphatic vessels</subject><subject>Calcium - metabolism</subject><subject>Cardiology. Vascular system</subject><subject>Disease Models, Animal</subject><subject>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</subject><subject>Emergency and intensive care: renal failure. Dialysis management</subject><subject>Immunohistochemistry</subject><subject>Intensive care medicine</subject><subject>Male</subject><subject>Matrix Metalloproteinase 2 - pharmacology</subject><subject>Matrix Metalloproteinase 9 - pharmacology</subject><subject>Medical sciences</subject><subject>Muscle, Smooth, Vascular - drug effects</subject><subject>Muscle, Smooth, Vascular - physiology</subject><subject>Probability</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Sensitivity and Specificity</subject><subject>Statistics, Nonparametric</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Vascular surgery: aorta, extremities, vena cava. Surgery of the lymphatic vessels</subject><subject>Vasoconstriction - drug effects</subject><subject>Vasoconstriction - physiology</subject><subject>Vasodilation - drug effects</subject><subject>Vasodilation - physiology</subject><issn>0741-5214</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1Lw0AQhveg2Fr9AV4kF71I4k52k02OUvyCihc9yjLZTOiWfNTdtNh_75YWehqYed6X4WHsBngCHPLHVbLa-iTlXCa8SLjIztiUKwlxloKcsEvvV5wDZIW6YBPIskyVoKbs5wNHZ_-ijkZs22HthpFsj55ivyZjG2si2y9tZUc79NHQRHNMHyLqR7cLGbPE3vrO7w9b9GbToovMEK5o9oErdt5g6-n6OGfs--X5a_4WLz5f3-dPi9iIvBhjUQMUYIQxMuWqqSqJmBOZskQSOZcouchFTRkJmao6LyVhWFZFjQYQUczY_aE3_P-7IT_qznpDbYs9DRuvc8VLBSADCAfQuMF7R41eO9uh22ngeu9Rr3TwqPceNS908Bgyt8fyTdVRfUocJQbg7ggEBdg2Dntj_YnL07IUSol_mQ2AgA</recordid><startdate>20041101</startdate><enddate>20041101</enddate><creator>CHEW, David K. W</creator><creator>CONTE, Michael S</creator><creator>KHALIL, Raouf A</creator><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20041101</creationdate><title>Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction</title><author>CHEW, David K. W ; CONTE, Michael S ; KHALIL, Raouf A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c368t-3d1181c3cc4207fbb4aa6eec99ae3604a40363de5e3427d694ea4a4b8dac1aaa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Animals</topic><topic>Aorta, Thoracic - drug effects</topic><topic>Aorta, Thoracic - pathology</topic><topic>Biological and medical sciences</topic><topic>Biopsy, Needle</topic><topic>Blood and lymphatic vessels</topic><topic>Calcium - metabolism</topic><topic>Cardiology. Vascular system</topic><topic>Disease Models, Animal</topic><topic>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</topic><topic>Emergency and intensive care: renal failure. Dialysis management</topic><topic>Immunohistochemistry</topic><topic>Intensive care medicine</topic><topic>Male</topic><topic>Matrix Metalloproteinase 2 - pharmacology</topic><topic>Matrix Metalloproteinase 9 - pharmacology</topic><topic>Medical sciences</topic><topic>Muscle, Smooth, Vascular - drug effects</topic><topic>Muscle, Smooth, Vascular - physiology</topic><topic>Probability</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Sensitivity and Specificity</topic><topic>Statistics, Nonparametric</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Vascular surgery: aorta, extremities, vena cava. Surgery of the lymphatic vessels</topic><topic>Vasoconstriction - drug effects</topic><topic>Vasoconstriction - physiology</topic><topic>Vasodilation - drug effects</topic><topic>Vasodilation - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CHEW, David K. W</creatorcontrib><creatorcontrib>CONTE, Michael S</creatorcontrib><creatorcontrib>KHALIL, Raouf A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of vascular surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CHEW, David K. W</au><au>CONTE, Michael S</au><au>KHALIL, Raouf A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction</atitle><jtitle>Journal of vascular surgery</jtitle><addtitle>J Vasc Surg</addtitle><date>2004-11-01</date><risdate>2004</risdate><volume>40</volume><issue>5</issue><spage>1001</spage><epage>1010</epage><pages>1001-1010</pages><issn>0741-5214</issn><coden>JVSUES</coden><abstract>Abdominal aortic aneurysm (AAA) is a common disease with as yet unclear cause. Increased matrix metalloproteinase (MMP) levels in the plasma and aorta are a consistent finding in AAA. Although the role of MMPs in AAA has largely been attributed to degradation of the extracellular matrix proteins, the effects of MMPs on the mechanisms of aortic contraction are unclear. The purpose of this study was to test the hypothesis that MMPs promote aortic dilation by inhibiting the Ca2+ mobilization mechanisms of smooth muscle contraction. Isometric contraction and 45Ca2+ influx were measured in aortic strips isolated from male Sprague-Dawley rats treated or not treated with MMP-2 and MMP-9. In normal Krebs solution (2.5 mmol/L Ca2+ ) phenylephrine (10-5 mol/L) caused contraction of the aortic strips, which was significantly inhibited (P &lt; .05) by MMP-2 (maximum, 48.9% +/- 5.0%) and to a greater extent by MMP-9 (maximum, 69.8% +/- 6.2%). The MMP-induced inhibition of phenylephrine contraction depended on concentration and time. The inhibitory effects of MMPs on phenylephrine contraction were reversible. In Ca2+ -free (2 mmol/L ethylene glycol bis[beta-aminoethyl ether]-N,N,N',N'-tetraacetic acid) Krebs solution phenylephrine caused a small contraction that was not inhibited by MMP-2 or MMP-9, which suggests that MMPs do not inhibit Ca2+ release from the intracellular stores. Membrane depolarization with 96 mmol/L of potassium chloride, which stimulates Ca2+ entry from the extracellular space, caused a time-dependent and reversible contraction, which was inhibited by MMP-2 and MMP-9. Histologic studies of MMP-treated tissues stained with hematoxylin-eosin or Verhoeff stain for elastin confirmed the absence of degradation of the extracellular matrix. MMP-2 and MMP-9 also caused significant inhibition of 45Ca2+ influx induced by phenylephrine and potassium chloride. These data suggest that MMP-2 and MMP-9 promote aortic dilation by inhibiting the Ca2+ entry mechanism of vascular smooth muscle contraction. Abdominal aortic aneurysm (AAA) is a slow and progressive disease. The late stages of AAA are characterized by degenerative changes in the extracellular matrix and smooth muscle components of the aortic wall. The present study describes novel inhibitory effects of matrix metalloproteinase (MMP) on the Ca2+ entry mechanisms of aortic smooth muscle contraction, even in the absence of extracellular matrix degradation. The MMP-induced inhibition of aortic contraction may further explain the role of increased MMP activity particularly during the early development of AAA. Chronic exposure to MMPs may lead to protracted inhibition of aortic contraction, progressive aortic dilation, and aneurysm formation. MMP-9 is a more potent inhibitor of aortic contraction than MMP-2, consistent with a more dominant role in AAA. Restoration and preservation of smooth muscle contractile function by specific inhibitors of MMPs may represent a new strategy in preventing the progression of small AAA.</abstract><cop>New York, NY</cop><pub>Elsevier</pub><pmid>15557917</pmid><doi>10.1016/j.jvs.2004.08.035</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0741-5214
ispartof Journal of vascular surgery, 2004-11, Vol.40 (5), p.1001-1010
issn 0741-5214
language eng
recordid cdi_proquest_miscellaneous_67097114
source MEDLINE; Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals
subjects Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Animals
Aorta, Thoracic - drug effects
Aorta, Thoracic - pathology
Biological and medical sciences
Biopsy, Needle
Blood and lymphatic vessels
Calcium - metabolism
Cardiology. Vascular system
Disease Models, Animal
Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
Emergency and intensive care: renal failure. Dialysis management
Immunohistochemistry
Intensive care medicine
Male
Matrix Metalloproteinase 2 - pharmacology
Matrix Metalloproteinase 9 - pharmacology
Medical sciences
Muscle, Smooth, Vascular - drug effects
Muscle, Smooth, Vascular - physiology
Probability
Rats
Rats, Sprague-Dawley
Sensitivity and Specificity
Statistics, Nonparametric
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Vascular surgery: aorta, extremities, vena cava. Surgery of the lymphatic vessels
Vasoconstriction - drug effects
Vasoconstriction - physiology
Vasodilation - drug effects
Vasodilation - physiology
title Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T11%3A16%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Matrix%20metalloproteinase-specific%20inhibition%20of%20Ca2+%20entry%20mechanisms%20of%20vascular%20contraction&rft.jtitle=Journal%20of%20vascular%20surgery&rft.au=CHEW,%20David%20K.%20W&rft.date=2004-11-01&rft.volume=40&rft.issue=5&rft.spage=1001&rft.epage=1010&rft.pages=1001-1010&rft.issn=0741-5214&rft.coden=JVSUES&rft_id=info:doi/10.1016/j.jvs.2004.08.035&rft_dat=%3Cproquest_cross%3E67097114%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67097114&rft_id=info:pmid/15557917&rfr_iscdi=true